Japan Could Become The First Country To Eradicate HIV

Updated Mar 7, 2025 | 05:00 PM IST

SummaryThe idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Japan Could Become The First Country To Eradicate HIV

Credits: Canva

Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

End of Article

H1N1 In Delhi: 166 Fresh Cases In 24 Hours, Tally Rises To 2,612

Updated Aug 28, 2026 | 11:57 AM IST

SummaryMost patients are presenting with flu-like symptoms, including cold, cough, body aches and upper respiratory tract infections. However, some doctors are also seeing atypical symptoms such as diarrhea also and myalgias, which are getting very, very frequent.
H1N1 In Delhi: 166 Fresh Cases In 24 Hours, Tally Rises To 2,612

Credit: iStock

India’s national capital is reporting a significant surge in influenza H1N1 cases. In the last 24 hours, Delhi reported 166 fresh H1N1 cases, up from 138 cases recorded the previous day, taking the cumulative tally to 2,612, officials said.

The total number of H1N1 cases in Delhi stood at 2,612, while cumulative Influenza-A cases were around 3,300, according to an official statement.

Delhi Reviews Hospital Preparedness

Health Minister Pankaj Kumar Singh inspected Indira Gandhi Hospital in Dwarka amid the rising number of H1N1 cases in the national capital and reviewed the hospital's and the Health Department's preparedness.

The Minister said he has been closely monitoring preparedness across hospitals.

Beyond Delhi, areas including Mumbai and Bengaluru have also reported a significant spike in H1N1 cases.

DG ICMR Dr. Rajiv Bahl said H1N1 in India is showing expected seasonal changes, with no unusual genetic shift detected.

“No cause for panic: seasonal influenza remains self-limiting; no new or unusual virus strain detected,” he added.

Doctors Flag Atypical H1N1 Symptoms

Influenza A (H1N1) is a seasonal respiratory infection that is mostly self-limiting in healthy adults. If symptoms persist beyond 5–6 days, or occur in young children, elderly persons or those with underlying medical conditions, consult a doctor or visit your nearest government health facility, the Health Ministry advised.

Dr. Atul Kakkar, Senior Consultant and Head of Department, Internal Medicine, Sir Ganga Ram Hospital, told HealthandMe that H1N1 cases are significantly higher than last year, possibly due in part to seasonal changes.

Most patients are presenting with flu-like symptoms, including cold, cough, body aches and upper respiratory tract infections.

However, doctors are also seeing atypical symptoms.

“We are seeing patients having diarrhea also and myalgias, which are getting very, very frequent.”

Patients at extreme ages are more prone to complications and may require oxygen, high-flow oxygen, NIV or BiPAP, he said. Those at higher risk include people who are unvaccinated against flu, patients undergoing chemotherapy, and those with COPD, bronchial asthma, cancer or those on immunosuppressive treatment.

H1N1 Can Affect The Heart

As per experts, H1N1 infection may also be associated with cardiovascular complications, including:

  • Heart inflammation
  • Abnormal heartbeats
  • Worsening heart failure
Dr. Saurabh Gupta, Associate Director, Internal Medicine, Yashoda Medicity, said H1N1 may cause fluctuations in heart rhythm or inflammation involving the heart.

“Those with pre-existing heart conditions should be more vigilant whilst they’re recuperating. As the infection puts more work on the body, you can find that previous heart problems are more noticeable,” he added.

H1N1 Can Affect The Eyes

While H1N1 primarily causes fever and respiratory symptoms, some people also have some eye discomfort and sudden vision changes.

Dr. Maitri Jindal Chowdhary, Consultant, Ophthalmology: Yashoda Medicity told HealthandMe that eye symptoms during H1N1 may manifest as a bit of redness, watery eyes, some irritation or dryness, which should resolve as the H1N1 is overcome. But a change in vision definitely warrant an eye professional’s attention.

The expert said that vision changes such as blurry or double vision, acute vision loss, seeing flashes of light or floaters or a drop in your vision should be brought to the attention of an eye doctor. Don’t automatically attribute such vision changes to your “flu”.

"Some eye concerns are of course not as serious. There might be some watering of eyes, slight discomfort that resolve as you feel better. However if symptoms such as sudden blurry vision persists, if eye irritation persists or worsens – you need to get yourself checked out.

Likewise if you feel pain in the eye, there’s an alarming redness, a lot of light sensitivity, swelling or an discharge - go get those eyes checked out," Dr. Maitri told HealthandMe.

Be very careful if you wear contact lenses. Do not wear them if your eyes become red, painful or vision blurring as this could worsen the issue. Remove your contacts immediately and seek attention.

End of Article

US FDA Approves Updated COVID Vaccines For 2026-27 Season: All You Should Know

Updated Aug 28, 2026 | 09:51 AM IST

SummaryFour COVID vaccines have been approved for use in the US after an advisory panel recommended that the shots target the dominant XFG variant.
US FDA Approves Updated COVID Vaccines For 2026-27 Season: All You Should Know

Credit: iStock

The US Food and Drug Administration (FDA) has approved updated COVID vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi for the 2026-27 season, the companies said.

Four COVID vaccines have been approved for use in the US after an advisory panel recommended that the shots target the dominant XFG variant.

What Are The New COVID Vaccines?

Moderna: mNEXSPIKE and Spikevax

  • Spikevax: Approved for people aged 6 months through 64 who have an underlying condition, and anyone aged 65 or older.
  • mNEXSPIKE: Approved for people aged 12 through 64 who have an underlying condition, and anyone aged 65 or older.
The mRNA-based vaccines target the XFG subvariant of the JN.1 coronavirus strain.

Pfizer-BioNTech: Comirnaty

It is approved for:

  • All adults aged 65 and older.
  • People aged 5 through 64 who have a condition that raises their risk of severe illness.
The vaccine targets the LP.8.1 strain of the coronavirus.

Novavax-Sanofi: Nuvaxovid

  • Nuvaxovid is the only protein-based COVID vaccine available in the US. It is approved for everyone aged 65 and older and for those aged 12 through 64 who have underlying conditions.

The vaccine targets the JN.1 strain.

When Will The Updated Shots Be Available?

All manufacturers had previously said they could make the updated shots in time for the 2026-27 immunization season, although Novavax could take longer to manufacture its vaccine.

The Donald Trump administration had shelved the universal COVID vaccine recommendation. It now recommends that everyone aged 6 months and older consult a healthcare provider before getting the shot.

In May, eight of the committee's nine experts voted in favor of targeting the XFG variant for the 2026-27 campaign.

For the 2025-26 season, the FDA had recommended that COVID shots target LP.8.1, a subvariant of the JN.1 strain. The CDC has yet to make an official recommendation for this year's vaccines.

Experts say the vaccines should begin reaching pharmacies and doctors' offices in September, CNN reported.

What Is The Current COVID Situation In The US?

The CDC's latest respiratory illness data, updated August 21, shows that national and regional COVID-19 activity is increasing, although overall acute respiratory illness causing people to seek healthcare remains very low.

Doctors have been reporting an increase in patients testing positive through the summer. But some physicians are noticing a change in how the illness is presenting.

Reports have emerged stating that COVID is resurfacing with new symptoms including nausea, vomiting and diarrhoea.

COVID-19-related visits to the emergency room are also increasing.

Recent reports from doctors in Georgia describe patients arriving with gastrointestinal symptoms alongside, or sometimes instead of, the more familiar respiratory symptoms.

Although these symptoms may seem unusual compared with the classic COVID presentation, nausea, vomiting and diarrhoea are not new symptoms of COVID-19.

The CDC has included nausea, vomiting and diarrhoea among the possible symptoms of COVID-19 for years.

Dr James Black, medical director of emergency services at Phoebe Putney Memorial Hospital in Albany, Georgia, said doctors are still seeing fever, cough and upper-respiratory symptoms, but added, “A lot of people are coming in with gastrointestinal symptoms - nausea, vomiting, diarrhea, sometimes to the point of mild dehydration.”

End of Article

Ebola Bundibugyo Virus: American Health Worker Had 10x Higher Viral Load In Throat Than Blood

Updated Aug 28, 2026 | 12:08 AM IST

SummaryEbola viruses are primarily known to attack the vascular system, damaging blood vessel integrity and disrupting the body’s ability to clot. But the throat of the 39-year-old American healthcare worker, infected with Bundibugyo in the Congo and later treated in Germany, carried more than 10 times as much viral RNA as his blood.
Ebola Bundibugyo Virus: American Health Worker Had 10x Higher Viral Load In Throat Than Blood

Credit: iStock

Even as the Ebola outbreak caused by the rare Bundibugyo Ebola virus continues to spread, a new case study has revealed a striking finding: the lesser-known virus can remain at very high levels in a patient’s throat.

Ebola viruses are primarily known to attack the vascular system, damaging blood vessel integrity and disrupting the body’s ability to clot. This can lead to severe fluid loss, organ failure and, in some cases, internal or external bleeding.

However, a case study of a 39-year-old American healthcare worker infected with Bundibugyo Ebola virus in the Democratic Republic of the Congo (DRC) found that his throat carried more than 10 times as much viral RNA as his blood.

The patient was later medically evacuated to Germany, where he received experimental treatment at a high-level isolation unit in Berlin.

Throat Carried 10 Times More Virus

On day five of illness, testing showed:

  • Throat: About 90 million viral RNA copies/mL
  • Blood plasma: About 7 million copies/mL
  • Difference: The throat had more than 10 times the viral RNA found in blood.

The case was published in Nature Medicine by researchers from Charité – Universitätsmedizin Berlin, with collaborators including the CDC, US Department of State, Robert Koch Institute, Emory University and Congo’s Institut National de Recherche Biomédicale.

How Was He Exposed?

The healthcare worker had performed an ultrasound nine days before symptoms began.

Eight days before symptoms, he performed two surgeries using standard personal protective equipment and reported no specific high-risk exposure.

He voluntarily isolated himself when symptoms began. His early symptoms included:

  • Severe muscle pain and malaise
  • 38.9°C fever despite acetaminophen
  • Positive pan-Ebola PCR on plasma by day two

By day three, he developed abdominal pain, vomiting, confusion and orthostatic symptoms.

Experimental Treatment Was Given

Bundibugyo Ebola virus has so far caused three recorded outbreaks, but there are currently no licensed vaccines or specific treatments for the disease.

The patient had received a dose of rVSV-ZEBOV 41 months earlier, but that vaccine targets the Zaire species.

He received the investigational antibody cocktail MBP134 on day four, along with a 200 mg loading dose of remdesivir off-label.

He reached Berlin on day five with thrombocytopenia, lymphopenia and elevated liver enzymes.

Viral RNA Cleared From Most Samples

By day 13, viral RNA was below detection levels in his:

  • Plasma
  • Throat
  • Urine
  • Stool

However, the virus was still detected in semen on day 20 but was gone by day 25. Three laboratories failed to culture live virus from throat, plasma or semen samples, the report said.

The researchers cautioned that this cannot be directly attributed to MBP134 because pre-treatment culture data were unavailable. The patient was discharged 22 days after symptom onset.

His Immune System Also Responded

Researchers found rising antibodies against the virus between days five and six, along with virus-specific IgM and IgA, suggesting that his own immune system mounted a response despite receiving monoclonal antibodies.

However, the researchers stressed that the case does not prove MBP134, remdesivir or their combination works. Larger studies are needed.

Congo Ebola Outbreak

Congo declared the outbreak in Ituri Province on May 15, 2026, followed by a WHO public health emergency of international concern two days later.

As of August 22, the ECDC reported:

  • 5,514 confirmed cases
  • 2,642 deaths
  • 4,607 cases and 2,065 deaths in Ituri
The WHO has described it as the largest Ebola outbreak ever reported in Congo. Uganda, which reported a small number of travel-linked cases, declared its outbreak over in late July.

End of Article